Full Prescribing Information
Prescribed for over 25 years
  • For over 25 years, physicians have prescribed CARAFATE® suspension
  • CARAFATE® is an established brand:
    • The only available branded sucralfate suspension on the market with no AB-‍rated equivalent
    • Widely prescribed by gastroenterologists and primary care physicians1
    • Greater than 160,000 prescribers make the choice to use CARAFATE1
    • Approximately 450,000 patients take CARAFATE each year1
Carafate packaging
For illustrative purposes only.
Write DAW (dispense as written) or the equivalent for your state to ensure your patient gets CARAFATE Suspension
There is no AB-rated generic substitute for CARAFATE Suspension2
View more information
Sucralfate tablets have not been demonstrated to be equivalent to CARAFATE Suspension.
CARAFATE® (sucralfate) Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

  • CARAFATE is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Please also see additional Important Safety Information below for CARAFATE.
Form a protective barrier with Carafate Suspension
Although the mechanism of CARAFATE Suspension’s ability to accelerate healing of duodenal ulcer is not fully defined, it is thought that antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site3
  • Administer CARAFATE only by the oral route. Do not administer intravenously as fatal complications, including pulmonary and cerebral emboli have occurred with inappropriate intravenous administration.
  • While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post-healing frequency or severity of duodenal ulceration.
  • Episodes of hyperglycemia have been reported in diabetic patients treated with sucralfate suspension. Close monitoring of glycemia in diabetic patients is recommended and adjustment of the anti-diabetic treatment dose during treatment with sucralfate suspension may be necessary.
Special Populations
  • Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum; aluminum accumulation and toxicity have been described in patients with renal impairment. Sucralfate should be used with caution in patients with chronic renal failure.
  • Safety and effectiveness in pediatric patients have not been established.
  • Dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range.
Drug Interactions
  • Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported.
  • Because of its potential to alter the absorption of some drugs, CARAFATE should be administered separately from other drugs when alterations in bioavailability are felt to be critical; in these cases patients should be monitored appropriately.
Adverse Reactions
  • The most common adverse reaction was constipation (2%).
Please also see full Prescribing Information for CARAFATE.
References: 1. Data on file, Allergan. 2. U.S. Food & Drug Administration. Drugs @FDA: FDA Approved Drug Products. ht‍tps:‍//ww‍w.accessdata.‍fda.‍g‍ov/‍scripts/cder/daf‍/index‍.cfm?event=overview.process&applno=019‍183. Accessed Ap‍ril 20‍19. 3. CARAFATE [package insert]. Madison, NJ: Allergan USA, Inc.; Ju‍ne 20‍18.
PLEASE NOTE: DO NOT REPLY TO THIS EMAIL. Emails sent to this account will not be read.
We respect your privacy. See our Privacy Policy.
Allergan Logo
Allergan® and its design are trademarks of Allergan, Inc.
CARAFATE® is a registered trademark of Aptalis Pharma Canada ULC, an Allergan affiliate.
© 2019 Allergan. All rights reserved.   CAR117111-v2   04/‍19
Allergan USA, Inc.
5‍ Giralda Farms
Mad‍ison, N‍J 07‍940
The information provided in this email is intended for U.S. healthcare professionals only.
The products described in this email may have different product labeling in countries outside the United States.
If you would prefer not to receive further messages from this sender, please click here and confirm your request.